Alzheimer's Disease Clinical Trial
Official title:
Comparison of Two Modes of Administration of the IADL Questionnaire
In France, about 1 million people 65 and older are diagnosed with dementia syndrome
characterized by cognitive decline and impairment of functional capacity. The assessment of
the level of functional autonomy is therefore an essential step in monitoring patients in
Memory Clinic and can be estimated by the Lawton IADL questionnaire, assessing the patients'
ability to perform daily tasks.
In the Memory Clinic, the first estimate of the level of patient autonomy is achieved during
a face-to-face interview between their primary caregiver and a nurse, using the IADL
questionnaire. This assessment should be renewed every year. The IADL questionnaire is part
of the information that the memories consultations shall transmit to the Alzheimer's
National Bank (BNA).
However, current practice has shown that the systematic collection is problematic in the
organization of Memory Clinic. It is thus expected to collect this questionnaire by phone in
order to measure changes in the level of autonomy during the disease, and improve the
completeness of this collection. A study is conducted with the main objective to measure the
reliability of the assessment of IADL questionnaires conducted during a telephone interview
with the caregiver of the patient, in comparison to the reference mode: the face-to-face
interview with the caregiver.
Materials and methods The experimental design of the study will be a randomized crossover
trial (crossover), including 394 patients divided into two branches. In the first part, the
collection of the IADL questionnaire will be performed according to the reference method in
the consultation (face-to-face interview with the nurse), the measurement will be repeated
at 1 month intervals by phone. In the second part the sequence of execution modes will be
reversed. The reliability of the measurement of the level of autonomy will be studied by
comparing repeated measurements based on handover modes. The correspondence between the
repeated measures will also be considered in terms of patient characteristics. The
feasibility of administration of the questionnaire by phone mode will be evaluated.
Expected results The mode of administration by phone should allow to obtain a reliable
measurement of the level of patient autonomy when the administration is carried out in a
standardized way. The study should also identify patients and situations for which this
method of administration by phone may be appropriate.
n/a
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Not yet recruiting |
NCT01940952 -
Zydena on Cognitive Function of Alzheimer's Disease Patients
|
Phase 3 |